ORHUB INC - ORHB STOCK NEWS

HippoFi, Inc. (OTC PINK:ORHB) announces the strategic launch of PURmarrow 360, a bone marrow aspirate device, in the United States. This innovative product aims to enhance bone growth in spine surgeries and improve patient healing by capturing the patient's own living cells without requiring centrifugation. The company emphasizes the purity and genetic makeup of the cells, highlighting the effectiveness of the product.

HippoFi's subsidiary, PUR Biologics, has obtained national approval to sell its biologic products throughout the Veterans Health Administration (VHA), the largest integrated healthcare system in the US. This milestone approval will expand the reach of PUR Biologics and provide veterans with advanced treatment options.

HippoFi, Inc. (OTC PINK: ORHB) announced a significant expansion of its biologics division, PUR Biologics, by adding 32 new distributors to its network. This growth reflects the increasing demand for PUR Biologics' high-quality products in the ortho-spine market, increasing the total number of distributors to 239. The company's leadership anticipates that this expansion will positively impact product sales in the second half of 2023. PUR Biologics specializes in biologic solutions for critical health issues, aiming to improve patient outcomes through innovative products. With a strong focus on quality and technology, PUR Biologics is well-positioned to lead in the biologics industry.

Goldman Small Cap Research has published a new research report on HippoFi, Inc. (OTCPK:ORHB), emphasizing its growth in the Regenerative Therapeutics market. The report forecasts a significant increase in sales, predicting an escalation from $2.9 million in fiscal year 2023 to $28 million in 2024 and $75 million in 2025. Driven by strong distributor relationships, including Precision Spine, HippoFi's PUR Biologics division is poised for success with innovative products for surgical applications. The report also highlights the potential for transformative product introductions and projects operating income will begin in 2024. Goldman assigns a price target based on a 4x price/revenue multiple for FY25E revenue, aligning with peer metrics.

BALTIMORE, MD / ACCESSWIRE / April 20, 2023 - Goldman Small Cap Research has released a new research report on HippoFi, Inc. (OTC PINK:ORHB), previously known as ORHub, Inc. The report highlights the company’s significant growth in its Regenerative Therapeutics division, with projected sales rising from $2.9M in FY23E to $28M in FY24E, and reaching $75M in FY25E. The company benefits from a strong distributor network, particularly with Precision Spine, offering innovative biological products for surgical procedures. HippoFi-Pay™, its digital payment division, is working on software to enhance logistical efficiencies. The analyst forecasts that HippoFi's price target aligns with peer groups at a 4x price/revenue multiple based on FY25E revenue.

PUR Biologics, a subsidiary of HippoFi (OTC PINK: ORHB), announced the issuance of a revolutionary patent for activating immune cells, positioning itself within the booming immunotherapy market projected to reach $271.84 billion by 2030. This breakthrough technology aims to enhance treatments for patients with immune-compromised systems and chronic pain. CEO CJ Wiggins emphasized the company’s commitment to advancing biologics and cellular-based immunotherapies. PUR Biologics seeks to restore the immune system's healing capabilities and develop novel anti-cancer therapies. The firm is dedicated to improving patient outcomes, particularly for the aging population, by leveraging innovative methodologies in immune activation and regenerative medicine. More details can be found at HippoFi.com.

PUR Biologics, a subsidiary of HippoFi (OTC PINK: ORHB), has launched PURfiberXP™, a processed demineralized extracellular matrix (d-ECM) aimed at enhancing bone regeneration and cellular integration. This innovation is designed to support healing in spine patients, featuring a unique fiber matrix that encourages cell migration. The global bone regeneration market is predicted to grow due to an aging population and increasing orthopedic disorders. PUR Biologics aims to strengthen its position in the biologics industry with this launch, providing spinal surgeons with advanced, easily implantable solutions. The company is committed to delivering state-of-the-art biologic products to improve patient care.

HippoFi, Inc. (OTC Pink: ORHB) has achieved Pink Current status with OTCMarkets, marking a significant milestone in its growth trajectory. This status reflects HippoFi's commitment to transparency and operational excellence, as highlighted by Executive Chairman CJ Wiggins. The company has enhanced its corporate governance and financial reporting practices, which were crucial for meeting OTCMarkets compliance. Ryan Fernan from PUR Biologics expressed optimism about the company's potential for profitable growth and innovation. This achievement positions HippoFi for future expansion, inviting investors to explore its strategic vision via its website.